Yahoo Search Búsqueda en la Web

Resultado de búsqueda

  1. Respiratory Investigation. 2024-05 | Journal article. DOI: 10.1016/j.resinv.2024.03.007. Contributors : Yosuke Fukuda; Yoshitaka Uchida; Koichi Ando; Ryo Manabe; Akihiko Tanaka; Hironori Sagara. Show more detail. Source : check_circle. Crossref. Complications of a lung biopsy for severe respiratory failure: A systematic review and meta-analysis.

  2. View Koichi Andos profile on LinkedIn, a professional community of 1 billion members. Managing Director at CIM Group · Experience: CIM Group, L.P. · Location: Los Angeles · 34 connections on...

  3. 27 de feb. de 2021 · The incidence of ≥grade 3 neutropenia and thrombocytopenia was significantly higher in ICIs+EP than IP, whereas the incidence of ≥grade 3 diarrhea was significantly lower in ICIs+EP than IP. These findings will help clinicians better select treatment strategies for ES-SCLC.

  4. 23 de jul. de 2021 · To date, there have been no head-to-head randomized controlled trials (RCTs) comparing the safety and efficacy of lorlatinib and alectinib in anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p) ALK-inhibitor‒naïve advanced non-small cell lung cancer (NSCLC).

  5. Abstract. Purpose: Radiotherapy using charged and/or high-linear energy transfer (LET) particles has a long history, starting with proton beams up to now carbon-ions. Radiation quality of particle beams is different from conventional photons, and therefore the biological effects of high-LET irradiation have attracted scientific interests of ...

  6. 27 de feb. de 2023 · Free full text in Europe PMC. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. Yamaoka T , Ohmori T , Ohba M , Arata S , Murata Y , Kusumoto S , Ando K , Ishida H , Ohnishi T , Sasaki Y. Mol Cancer Res, 15 (7):915-928, 13 Mar 2017. Cited by: 25 articles | PMID: 28289161.

  7. Koichi ANDO, Visiting Professor | Cited by 2,812 | of Gunma University, Maebashi (Gundai) | Read 73 publications | Contact Koichi ANDO